All
Relegating Cancer to the Back Seat
March 31st 2018"As I’ve endured my time with cancer, I’ve come to the realization that I’ve given it preferential treatment. For the past few years, I’ve given cancer the front seat and not only that, sometimes, I’ve even allowed cancer to take the driver’s wheel. I’ve become a passenger on my own life’s journey."
Women with Recurrent Ovarian Cancer Should Be Screened for Various Biomarkers
March 29th 2018Although genomic profiling successfully identifies those with microsatellite instability status who may benefit from PD-1 inhibitor therapy, a vast amount of women may be missed if they are not also tested for high tumor mutation burden too.
FDA Approves Blincyto for Patients with ALL Who Have Minimal Residual Disease
March 29th 2018Blincyto (blinatumomab) was granted approval by the Food and Drug Administration (FDA) to treat patients who have B-cell precursor acute lymphoblastic leukemia (ALL), who are in remission but still have minimal residual disease (MRD).